A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies

Martina Meduri, Giorgia Gregoraci, Valentina Baglivo, Matteo Balestrieri, Miriam Isola, Paolo Brambilla

Research output: Contribution to journalArticle

Abstract

Background Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). However, no prior investigation considered both randomized clinical trials (RCTs) and non-RCTs. We here evaluated the efficacy and safety of ARP compared with placebo (PCB) and other drugs at 3- and 12-weeks in adult and pediatric population including, for the first time, both observational and controlled studies. Methods All studies were systematically located by searching electronic sources (EMBASE, MEDLINE, CINHAIL, PsychINFO, Cochrane Central Register of Controlled Trials, Scopus and ClinicalTrials.gov) till June 30th, 2015. The primary outcome was ARP efficacy (mean change from baseline in Young Mania Rating Scale); secondary outcomes regarded acceptability and safety. Results Sixteen RCTs and 6 non-RCTs met our inclusion criteria; 2505 and 2932 patients were included in the analyses of acute and stabilization phase, respectively. In both the acute and stabilization phases ARP efficacy was superior to PCB and comparable to other drugs. The safety profile was similar to other drugs considering in particular sedation, akathisia, weight gain, extrapyramidal and gastroenteric symptoms, with a significant lower risk of hyperprolactinemia particularly at 12-weeks. Limitations Data on failed trials are generally limited. Conclusions ARP resulted to be an effective treatment in children and adults with BD at 3- and 12-weeks both in a controlled experimental setting or in the real world clinical practice, being poorly associated with hyperprolactinemia. Larger studies are needed to confirm our results related to the maintenance phases and to the pediatric bipolar population.

Original languageEnglish
Pages (from-to)187-208
Number of pages22
JournalJournal of Affective Disorders
Volume191
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Bipolar Disorder
Observational Studies
Meta-Analysis
Randomized Controlled Trials
Pediatrics
Safety
Hyperprolactinemia
Placebos
Pharmaceutical Preparations
Psychomotor Agitation
MEDLINE
Population
Weight Gain
Maintenance
Aripiprazole
Therapeutics
Non-Randomized Controlled Trials

Keywords

  • Akathisia
  • Extrapyramidal symptoms
  • Gastroenteric symptoms
  • Haloperidol
  • Hyperprolactinemia
  • Lithium
  • Safety
  • Sedation
  • Weight gain

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. / Meduri, Martina; Gregoraci, Giorgia; Baglivo, Valentina; Balestrieri, Matteo; Isola, Miriam; Brambilla, Paolo.

In: Journal of Affective Disorders, Vol. 191, 01.02.2016, p. 187-208.

Research output: Contribution to journalArticle

Meduri, Martina ; Gregoraci, Giorgia ; Baglivo, Valentina ; Balestrieri, Matteo ; Isola, Miriam ; Brambilla, Paolo. / A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. In: Journal of Affective Disorders. 2016 ; Vol. 191. pp. 187-208.
@article{14ef370b25334add8790452e9e907666,
title = "A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies",
abstract = "Background Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). However, no prior investigation considered both randomized clinical trials (RCTs) and non-RCTs. We here evaluated the efficacy and safety of ARP compared with placebo (PCB) and other drugs at 3- and 12-weeks in adult and pediatric population including, for the first time, both observational and controlled studies. Methods All studies were systematically located by searching electronic sources (EMBASE, MEDLINE, CINHAIL, PsychINFO, Cochrane Central Register of Controlled Trials, Scopus and ClinicalTrials.gov) till June 30th, 2015. The primary outcome was ARP efficacy (mean change from baseline in Young Mania Rating Scale); secondary outcomes regarded acceptability and safety. Results Sixteen RCTs and 6 non-RCTs met our inclusion criteria; 2505 and 2932 patients were included in the analyses of acute and stabilization phase, respectively. In both the acute and stabilization phases ARP efficacy was superior to PCB and comparable to other drugs. The safety profile was similar to other drugs considering in particular sedation, akathisia, weight gain, extrapyramidal and gastroenteric symptoms, with a significant lower risk of hyperprolactinemia particularly at 12-weeks. Limitations Data on failed trials are generally limited. Conclusions ARP resulted to be an effective treatment in children and adults with BD at 3- and 12-weeks both in a controlled experimental setting or in the real world clinical practice, being poorly associated with hyperprolactinemia. Larger studies are needed to confirm our results related to the maintenance phases and to the pediatric bipolar population.",
keywords = "Akathisia, Extrapyramidal symptoms, Gastroenteric symptoms, Haloperidol, Hyperprolactinemia, Lithium, Safety, Sedation, Weight gain",
author = "Martina Meduri and Giorgia Gregoraci and Valentina Baglivo and Matteo Balestrieri and Miriam Isola and Paolo Brambilla",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.jad.2015.11.033",
language = "English",
volume = "191",
pages = "187--208",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies

AU - Meduri, Martina

AU - Gregoraci, Giorgia

AU - Baglivo, Valentina

AU - Balestrieri, Matteo

AU - Isola, Miriam

AU - Brambilla, Paolo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). However, no prior investigation considered both randomized clinical trials (RCTs) and non-RCTs. We here evaluated the efficacy and safety of ARP compared with placebo (PCB) and other drugs at 3- and 12-weeks in adult and pediatric population including, for the first time, both observational and controlled studies. Methods All studies were systematically located by searching electronic sources (EMBASE, MEDLINE, CINHAIL, PsychINFO, Cochrane Central Register of Controlled Trials, Scopus and ClinicalTrials.gov) till June 30th, 2015. The primary outcome was ARP efficacy (mean change from baseline in Young Mania Rating Scale); secondary outcomes regarded acceptability and safety. Results Sixteen RCTs and 6 non-RCTs met our inclusion criteria; 2505 and 2932 patients were included in the analyses of acute and stabilization phase, respectively. In both the acute and stabilization phases ARP efficacy was superior to PCB and comparable to other drugs. The safety profile was similar to other drugs considering in particular sedation, akathisia, weight gain, extrapyramidal and gastroenteric symptoms, with a significant lower risk of hyperprolactinemia particularly at 12-weeks. Limitations Data on failed trials are generally limited. Conclusions ARP resulted to be an effective treatment in children and adults with BD at 3- and 12-weeks both in a controlled experimental setting or in the real world clinical practice, being poorly associated with hyperprolactinemia. Larger studies are needed to confirm our results related to the maintenance phases and to the pediatric bipolar population.

AB - Background Aripiprazole (ARP) has been shown to be effective in the treatment of bipolar disorder (BD). However, no prior investigation considered both randomized clinical trials (RCTs) and non-RCTs. We here evaluated the efficacy and safety of ARP compared with placebo (PCB) and other drugs at 3- and 12-weeks in adult and pediatric population including, for the first time, both observational and controlled studies. Methods All studies were systematically located by searching electronic sources (EMBASE, MEDLINE, CINHAIL, PsychINFO, Cochrane Central Register of Controlled Trials, Scopus and ClinicalTrials.gov) till June 30th, 2015. The primary outcome was ARP efficacy (mean change from baseline in Young Mania Rating Scale); secondary outcomes regarded acceptability and safety. Results Sixteen RCTs and 6 non-RCTs met our inclusion criteria; 2505 and 2932 patients were included in the analyses of acute and stabilization phase, respectively. In both the acute and stabilization phases ARP efficacy was superior to PCB and comparable to other drugs. The safety profile was similar to other drugs considering in particular sedation, akathisia, weight gain, extrapyramidal and gastroenteric symptoms, with a significant lower risk of hyperprolactinemia particularly at 12-weeks. Limitations Data on failed trials are generally limited. Conclusions ARP resulted to be an effective treatment in children and adults with BD at 3- and 12-weeks both in a controlled experimental setting or in the real world clinical practice, being poorly associated with hyperprolactinemia. Larger studies are needed to confirm our results related to the maintenance phases and to the pediatric bipolar population.

KW - Akathisia

KW - Extrapyramidal symptoms

KW - Gastroenteric symptoms

KW - Haloperidol

KW - Hyperprolactinemia

KW - Lithium

KW - Safety

KW - Sedation

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=84949035164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949035164&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2015.11.033

DO - 10.1016/j.jad.2015.11.033

M3 - Article

C2 - 26674213

AN - SCOPUS:84949035164

VL - 191

SP - 187

EP - 208

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -